Neuropathic pain management follows NICE CG173 guidance for diabetic peripheral neuropathic pain: First-line pharmacological options: Duloxetine (60 mg once daily) an SNRI licensed for diabetic peripheral neuropathic pain
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-comparator controlled phase 2 trial Rosenstock J, et al
Este portador a L-carnitina , graas qual os cidos gordos ativados so desviados para a oxidao e no so usados pelo organismo na neoformao de triglicridos, limitando a biodisponibilidade citoplasmtica de cidos gordos ativados
van Strijp JA, van Kessel KP, Miltenburg LA et al (1988) Attachment of human polymorphonuclear leukocytes to herpes simplex virus-infected fibroblasts mediated by antibody-independent complement activation